To assess the importance of intracellular signalling pathways and its deregulation in adiposity and diabetes-related insulin resistance, liver tissue samples of patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)will be analyzed prospectively from a liver tissue bank.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2007-12-17; most recent amendment 2012-02-23.
Status change: Not Yet Recruiting → Recruiting2008-06-25